RT Journal Article
T1 Secretory phospholipase A2 expression and activity in preterm clinical chorioamnionitis with fetal involvement
A1 De Luca, Daniele
A1 Foligno, Silvia
A1 Autilio, Chiara
A1 Vivanti, Alexandre
A1 Vandekerckhove, Melanie
A1 Martinovic, Jelena
A1 Raschetti, Roberto
A1 Guillot, Löic
A1 Touqui, Lhoussaine
AB Secretory phospholipase A2 (sPLA2) regulates the first step of inflammatory cascade and is involved in several pathological processes. sPLA2 also plays a role in preterm labor and parturition, since they are triggered by inflammatory mediators such as prostaglandins. Interestingly, chorioamnionitis (i.e., the presence of intrauterine inflammation) is also often associated with preterm birth. We aimed to verify if chorioamnionitis with fetal involvement modifies sPLA2 activity and expression profile in mothers and neonates delivered prematurely. We collected maternal plasma and amniotic fluid, as well as bronchoalveolar lavage fluid from preterm neonates born to mothers with or without clinical chorioamnionitis with fetal involvement. We measured concentrations of sPLA2 subtype-IIA and -IB, total enzyme activity, and proteins. Urea ratio was used to obtain epithelial lining fluid concentrations. Enzyme activity measured in maternal plasma (P < 0.001) and amniotic fluid (P < 0.001) was higher in chorioamnionitis cases than in controls. This was mainly due to the increased production of sPLA2-IIA, as the subtype -IB was present in a smaller amount and was similar between the two groups; sPLA2-IIA was increased in epithelial lining fluid (P = 0.045) or increased, although without statistical significance, in maternal plasma (P = 0.06) and amniotic fluid (P = 0.08) of chorioamnionitis cases. Cytokines that are known to increase sPLA2-IIA expression (TNF-a and IL-1b) or whose expression was increased by sPLA2-IIA (IL-8) were higher in histologically confirmed chorioamnionitis [TNF-a (P = 0.028), IL-1b (P < 0.001), and IL-8 (P = 0.038)]. These data represent the basis for future studies on sPLA2-IIA inhibition to prevent deleterious consequences of chorioamnionitis and preterm birth.
PB American Physiological Society
SN 1040-0605, Electronic: 1522-1504
YR 2022
FD 2022-06-28
LK https://hdl.handle.net/20.500.14352/72491
UL https://hdl.handle.net/20.500.14352/72491
LA eng
NO Association pour le développement et la Recherche en Néonatologie ((Association for the Research and Development in Neonatology)
DS Docta Complutense
RD 27 abr 2024